US Diabetes Market Outlook 2020
Diabetes has been on the rise for the last few years because of factors such as increased life span of people, hectic lifestyles and increased intake of fatty food. The largest number of cases of diabetes and pre-diabetes are found in the United States, with many still unaware about their diabetes or pre-diabetes condition. It has been estimated that the prevalence of diabetes will be 14% by 2030 in the US. This is likely to put a major burden on healthcare cost of the country. Studies have shown that the total healthcare expenditure in US was US$ 281 Billion in 2014 which was the largest share of the world healthcare expenditure.
The US diabetes care market is segmented into three parts, namely- anti-diabetic drugs segment, insulin delivery devices segment and monitoring and diagnostic devices segment. The most significant growth in the US market has been seen in continuous blood glucose meters, insulin pens, insulin pumps, and anti-diabetic drugs.
The report, “US Diabetes Market Outlook 2020”, highlights the US diabetes market by each segment. The market for each segment has been thoroughly studied and the future market scenario has been forecasted. The prevalence of diabetes and its cost implications have also been indicated in the report. The drivers and challenges of this market have been discussed along with the latest trends and developments. Additionally, information is provided about the key players in this market as well as the steps taken by the government to promote the market. The aforementioned information will help clients in formulating strategies and assessing opportunities in the US diabetes market.
The US diabetes care market is segmented into three parts, namely- anti-diabetic drugs segment, insulin delivery devices segment and monitoring and diagnostic devices segment. The most significant growth in the US market has been seen in continuous blood glucose meters, insulin pens, insulin pumps, and anti-diabetic drugs.
The report, “US Diabetes Market Outlook 2020”, highlights the US diabetes market by each segment. The market for each segment has been thoroughly studied and the future market scenario has been forecasted. The prevalence of diabetes and its cost implications have also been indicated in the report. The drivers and challenges of this market have been discussed along with the latest trends and developments. Additionally, information is provided about the key players in this market as well as the steps taken by the government to promote the market. The aforementioned information will help clients in formulating strategies and assessing opportunities in the US diabetes market.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. MARKET OVERVIEW
4. PATIENT PROFILE ANALYSIS
5. COST IMPLICATIONS
6. DRIVERS AND CHALLENGES
6.1 Drivers for Diabetes Market
6.1.1 Obesity Leading to Diabetes
6.1.2 Rising Disposable Income
6.1.3 Increasing Life Span of People
6.1.4 Increased Awareness about Diabetes Care
6.2 Challenges
6.2.1 Traditional Remedies for Diabetes Care
6.2.2 High Cost of Anti-diabetic Medication and Diagnostic Devices
6.2.3 Long Product Approval Process
7. DIABETES DRUGS MARKET
7.1 Oral Anti-Diabetic Drugs Market
7.2 Insulin Market
8. INSULIN DELIVERY DEVICES MARKET
8.1 Insulin Pump
8.2 Insulin Pen
8.3 Insulin Syringes
8.4 Insulin Jet Injectors
8.5 Oral Insulin
8.6 Inhalable Insulin
9. GLUCOSE MONITORING DEVICES MARKET
9.1 Glucose Test Strips
9.2 Lancets
9.3 Blood Glucose Meter
9.4 Continuous Blood Glucose Monitors
10. TRENDS AND DEVELOPMENTS
10.1 Glucose Meters for Easy Detection of Diabetes
10.2 Novel Drugs Keep Diabetes in Control
10.3 Islet Cell Transplantation- Hope for Diabetes Patients
11. GOVERNMENT INITIATIVES
12. COMPETITIVE LANDSCAPE
12.1 Drugs
12.1.1 Pfizer
12.1.2 GlaxoSmithKline
12.1.3 Takeda
12.1.4 Merck
12.2 Insulin Delivery Devices
12.2.1 Novo Nordisk
12.2.2 Eli Lilly
12.2.3 Sanofi
12.2.4 Medtronic Inc.
12.3 Glucose Monitoring Devices
12.3.1 Roche
12.3.2 Bayer
12.3.3 Abbott Laboratories
2. RESEARCH METHODOLOGY
3. MARKET OVERVIEW
4. PATIENT PROFILE ANALYSIS
5. COST IMPLICATIONS
6. DRIVERS AND CHALLENGES
6.1 Drivers for Diabetes Market
6.1.1 Obesity Leading to Diabetes
6.1.2 Rising Disposable Income
6.1.3 Increasing Life Span of People
6.1.4 Increased Awareness about Diabetes Care
6.2 Challenges
6.2.1 Traditional Remedies for Diabetes Care
6.2.2 High Cost of Anti-diabetic Medication and Diagnostic Devices
6.2.3 Long Product Approval Process
7. DIABETES DRUGS MARKET
7.1 Oral Anti-Diabetic Drugs Market
7.2 Insulin Market
8. INSULIN DELIVERY DEVICES MARKET
8.1 Insulin Pump
8.2 Insulin Pen
8.3 Insulin Syringes
8.4 Insulin Jet Injectors
8.5 Oral Insulin
8.6 Inhalable Insulin
9. GLUCOSE MONITORING DEVICES MARKET
9.1 Glucose Test Strips
9.2 Lancets
9.3 Blood Glucose Meter
9.4 Continuous Blood Glucose Monitors
10. TRENDS AND DEVELOPMENTS
10.1 Glucose Meters for Easy Detection of Diabetes
10.2 Novel Drugs Keep Diabetes in Control
10.3 Islet Cell Transplantation- Hope for Diabetes Patients
11. GOVERNMENT INITIATIVES
12. COMPETITIVE LANDSCAPE
12.1 Drugs
12.1.1 Pfizer
12.1.2 GlaxoSmithKline
12.1.3 Takeda
12.1.4 Merck
12.2 Insulin Delivery Devices
12.2.1 Novo Nordisk
12.2.2 Eli Lilly
12.2.3 Sanofi
12.2.4 Medtronic Inc.
12.3 Glucose Monitoring Devices
12.3.1 Roche
12.3.2 Bayer
12.3.3 Abbott Laboratories
LIST OF FIGURES:
Figure 3-1: Diabetes Market (Billion US$), 2013 & 2014
Figure 4-1: Prevalence of Diabetes (%), 2014 & 2030
Figure 4-2: Number of Diabetic Population (Million), 2014 & 2030
Figure 5-1: Total Healthcare Expenditure on Diabetes (Billion US$)-US vs. RoW, 2014
Figure 5-2: Cost per Person (US$) - US vs. RoW for People with Diabetes, 2014
Figure 6-1: Personal Disposable Income (Billion US$), 2008-2014
Figure 6-2: Population above 65 Years (Million), 2008-2014
Figure 7-1: Oral Diabetic Drugs Market (Billion US$), 2014-2020
Figure 7-2: Insulin Market (Billion US$), 2014-2020
Figure 7-3: Share of Key Players in Modern Insulin Market (FY 2013)
Figure 8-1: Insulin Pumps Market (Billion US$), 2014-2020
Figure 8-2 Shares of Key Players in US Insulin Pump Market (2013)
Figure 8-3: Insulin Pen Devices Market (Billion US$), 2014-2020
Figure 8-4: Insulin Syringes Market (Billion US$), 2014-2020
Figure 8-5: Insulin Jet Injectors Market (Billion US$), 2014-2020
Figure 9-1: Glucose Test Strips Market (Billion US$), 2014-2020
Figure 9-2: Lancets Market (Billion US$), 2014-2020
Figure 9-3: Blood Glucose Meter Market (Billion US$), 2014-2020
Figure 9-4: Continuous Blood Glucose Monitoring Market (Billion US$), 2014-2020
Figure 12-1: Pfizer - Breakup of Revenue by Geographies (%), 2014
Figure 12-2: GlaxoSmithKline - Breakup of Revenue by Geographies (%), 2014
Figure 12-3: Takeda - Breakup of Revenue by Geographies (%), 2014
Figure 12-4: Merck - Breakup of Revenue by Geographies (%), 2014
Figure 12-5: Novo Nordisk - Breakup of Revenue by Geographies (%), 2014
Figure 12-6: Eli Lilly - Breakup of Revenue by Geographies (%), 2014
Figure 12-7: Sanofi - Breakup of Revenue by Geographies (%), 2014
Figure 12-8: Medtronic Inc. - Breakup of Revenue by Geographies (%), 2014
Figure 12-9: Roche - Breakup of Revenue by Geographies (%), 2014
Figure 12-10: Bayer - Breakup of Revenue by Geographies (%), 2014
Figure 12-11: Abbott Laboratories - Breakup of Revenue by Geographies (%), 2014
Figure 3-1: Diabetes Market (Billion US$), 2013 & 2014
Figure 4-1: Prevalence of Diabetes (%), 2014 & 2030
Figure 4-2: Number of Diabetic Population (Million), 2014 & 2030
Figure 5-1: Total Healthcare Expenditure on Diabetes (Billion US$)-US vs. RoW, 2014
Figure 5-2: Cost per Person (US$) - US vs. RoW for People with Diabetes, 2014
Figure 6-1: Personal Disposable Income (Billion US$), 2008-2014
Figure 6-2: Population above 65 Years (Million), 2008-2014
Figure 7-1: Oral Diabetic Drugs Market (Billion US$), 2014-2020
Figure 7-2: Insulin Market (Billion US$), 2014-2020
Figure 7-3: Share of Key Players in Modern Insulin Market (FY 2013)
Figure 8-1: Insulin Pumps Market (Billion US$), 2014-2020
Figure 8-2 Shares of Key Players in US Insulin Pump Market (2013)
Figure 8-3: Insulin Pen Devices Market (Billion US$), 2014-2020
Figure 8-4: Insulin Syringes Market (Billion US$), 2014-2020
Figure 8-5: Insulin Jet Injectors Market (Billion US$), 2014-2020
Figure 9-1: Glucose Test Strips Market (Billion US$), 2014-2020
Figure 9-2: Lancets Market (Billion US$), 2014-2020
Figure 9-3: Blood Glucose Meter Market (Billion US$), 2014-2020
Figure 9-4: Continuous Blood Glucose Monitoring Market (Billion US$), 2014-2020
Figure 12-1: Pfizer - Breakup of Revenue by Geographies (%), 2014
Figure 12-2: GlaxoSmithKline - Breakup of Revenue by Geographies (%), 2014
Figure 12-3: Takeda - Breakup of Revenue by Geographies (%), 2014
Figure 12-4: Merck - Breakup of Revenue by Geographies (%), 2014
Figure 12-5: Novo Nordisk - Breakup of Revenue by Geographies (%), 2014
Figure 12-6: Eli Lilly - Breakup of Revenue by Geographies (%), 2014
Figure 12-7: Sanofi - Breakup of Revenue by Geographies (%), 2014
Figure 12-8: Medtronic Inc. - Breakup of Revenue by Geographies (%), 2014
Figure 12-9: Roche - Breakup of Revenue by Geographies (%), 2014
Figure 12-10: Bayer - Breakup of Revenue by Geographies (%), 2014
Figure 12-11: Abbott Laboratories - Breakup of Revenue by Geographies (%), 2014
LIST OF TABLES:
Table 4-1: Diabetic Patients in Age Group 20-79 Years ('000), 2013 & 2030
Table 12-1: Pfizer - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-2: GlaxoSmithKline - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-3: Takeda - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-4: Merck - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-5: Novo Nordisk - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-6: Eli Lilly - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-7: Sanofi - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-8: Medtronic Inc. - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-9: Roche - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-10: Bayer - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-11: Abbott Laboratories - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 4-1: Diabetic Patients in Age Group 20-79 Years ('000), 2013 & 2030
Table 12-1: Pfizer - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-2: GlaxoSmithKline - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-3: Takeda - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-4: Merck - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-5: Novo Nordisk - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-6: Eli Lilly - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-7: Sanofi - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-8: Medtronic Inc. - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-9: Roche - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-10: Bayer - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-11: Abbott Laboratories - Revenue by Business Segments (Billion US$), 2013 & 2014
